← Browse by Condition
Medical Condition

locally advanced unresectable or metastatic gastric cancer

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3
NCT06177041 Phase 3
Recruiting

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Enrollment
486 pts
Location
China
Sponsor
FutureGen Biopharmaceutical (B...
View Trial →